Figure 1.
The different imaging modalities in a 42-year-old man with a radioiodine-refractory differentiated thyroid cancer. Computed tomography scan of thorax (a); post 131I ablation whole-body scan (b); 99mTc octreotide scintigraphy (c); post 177Lu-DOTATATE whole-body imaging (d); 2 and 24 h prostate-specific membrane antigen scintigraphy (e and f) and post 177Lu-prostate-specific membrane antigen whole-body imaging (g)